Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
InSightec |
---|---|
Information provided by: | InSightec |
ClinicalTrials.gov Identifier: | NCT00147108 |
The primary objective of this pivotal study is to evaluate the safety and efficacy of FUS treatment of breast fibroadenomas. Our hypothesis is that FUS lesion ablation of a fibroadenoma will have the following results: a.
lead to a decrease in lesion cross-sectional area of > 50% on palpation, and >65% in lesion volume as measured by MRI (both calculations assume an elliptical shape of the lesion in all 3 dimensions). b. this decrease in size, along with the softening of the treated volume will result in satisfactory clinical results in greater than 50 % of the patients.
Condition | Intervention | Phase |
---|---|---|
Breast Fibroadenoma |
Device: ExAblate 2000 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 3 Study of MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas |
Enrollment: | 102 |
Many patients are now diagnosed with breast fibroadenomas. These are generally detected during breast self-exams, or annual physicals as a smooth, rubbery, oval/elliptical lump in the breast. These patients then go on to receive mammograms, sonograms and usually a core biopsy for the differential diagnosis of benign disease (fibroadenoma) vs breast cancer. Although fibroadenomas are benign, they can be of great concern to the patient because of their ability to mask the presence of other lumps in the breast, they can be painful, cause a physical deformity of the breast or have other symptoms. The current treatment is surgical excision. Surgical removal is invasive and may be cosmetically undesirable to some patients. It would be advantageous to develop a non-invasive ablative method for treatment of this disease. Measures of the clinical success of patients who elect surgical removal of fibroadenomas are generally subjective, and evaluated primarily by the patient (lack of palpable lesion, pain free, and an acceptable cosmetic result). A non-randomized study is proposed to allow for a more practical approach in subject recruitment. Analysis on safety and efficacy will be performed through the use of MRI evaluation and physical exams.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
University MRI | |
Boca Raton, Florida, United States, 33431 | |
United States, Massachusetts | |
Brigham & Women's Hospital | |
Boston, Massachusetts, United States, 02115 | |
United States, New Jersey | |
Virtua | |
Voorhees, New Jersey, United States, 08043 | |
United States, New York | |
Cornell Vascular | |
New York, New York, United States, 10022 | |
Japan | |
Breastopia Namba Hospital | |
Miyazaki-ken, Japan, 880-0052 |
Principal Investigator: | Clare Tempany, M.D. | Brigham and Women's Hospital |
Principal Investigator: | Robert Min, M.D. | Cornell Vascular |
Principal Investigator: | Fred Steinberg, M.D. | University MRI |
Principal Investigator: | Mark DeLaurentis, M.D. | Virtua |
Principal Investigator: | Hidemi Furusawa, M.D. | Breastopia Hospital |
Study ID Numbers: | BF002 |
Study First Received: | September 2, 2005 |
Last Updated: | January 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00147108 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Breast Cancer |
Fibroadenoma Neoplasms, Connective and Soft Tissue Breast Neoplasms Neoplasms, Glandular and Epithelial |
Fibroadenoma Neoplasms, Connective and Soft Tissue Neoplasms Neoplasms by Histologic Type |
Neoplasms, Fibroepithelial Neoplasms, Connective Tissue Neoplasms, Fibrous Tissue Neoplasms, Glandular and Epithelial |